You are using an outdated browser. For an optimal and safe experience we advise you to update your browser. Click here for the latest versions.

Programme

REGISTRATION 
09:30 - 10:00 Coffee and registration
   
OPENING & WELCOME
10:00 - 10:10 Welcome
  Prof. Sybe Schaap
   
SESSION 1: Plenary session - Novel developments
10:15 - 11:00 Opportunities and Challenges for RNA vaccines and therapeutics
  Prof. Robin Shattock - Department of Infectious Disease, Imperial College London
11:00 - 11:45 Opportunities and Challenges for virus-based therapeutics in humans
  Prof. Ron Fouchier - Department of Viroscience, Erasmus Medical Center
   
11:45 - 13:15 Lunch
   
SESSION 2: Clinical and veterinary therapeutics
13:15 - 13:45 First-in-human clinical trial with an alphavirus-based replicon vaccine against HPV-induced cancers
  Prof. Toos Daemen - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen
13:45 - 14:15 Vaccine platform technologies within Animal Health – Possibilities and limitations
  Dr. Martijn Langereis - MSD Animal Health
   
SESSION 3: Biosafety aspects
14:15 - 14:45 Viral replicon systems and their biosafety aspects  - Inventory and description of viral replicon systems and characteristics relevant for risk assessment
  Dr. Karen van der Meulen  - Perseus B.V.
14:45 - 15:15 Rise of the RNA machines - self-amplification as next step in mRNA vaccine design
  Dr. Gorben Pijlman - Laboratory of Virology, Wageningen University
   
15:15 - 15:45 Coffee Break
   
SESSION 4: Considerations for regulation
15:45 - 16:05 Clinical studies with GMOs in the Netherlands: Regulations in a rapidly emerging field
  Dr. Marco Gielkens - GMO office, National Institute for Public Health and the Environment
16:05 - 16:25 Biological containment and the UK regulatory approach to Contained Use and Deliberate Release of GM vaccines
  Dr. Sean Simpkins - Department for Environment Food and Rural Affairs
16:25 - 16:45 To be announced
16:45 - 17:15 Discussion on future proof regulation
 
CONCLUDING REMARKS
17:15 - 17:25 Concluding remarks